Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer

K. Y. Shum, M. G. Kris, R. J. Gralla, M. T. Burke, L. D. Marks, R. T. Heelan

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

10-Ethyl-10-deaza-aminopterin (10-EDAM) is an analog of methotrexate that differs from its compound by modification of the N10 position and demonstrates greater preclinical antitumor activity and less toxicity. In this phase II trial, 20 patients with stage III or IV non-small-cell lung cancer (NSCLC) were administered 10-EDAM at a dose of 80 mg/m2 once weekly for 5 weeks. No patient had previously received chemotherapy. Nineteen of the 20 patients were adequately treated for response assessment. Six of 19 patients (32%) experienced a major objective response (exact 95% confidence limits, 15% to 55%). The median duration of response has not been reached and will exceed 13 months. Mucositis was the most common toxicity observed. Leukopenia was seen in only 10%, and 15% had platelet nadirs < 100,000/μL. At the dosage and schedule used, 10-EDAM is an active agent in patients with NSCLC who are previously untreated with chemotherapy with a predicted response rate ≥ 15% (P = .05). Because of its level of antitumor activity and the fact that 10-EDAM causes minimal myelosuppression, it is a suitable agent for further study in combination with other chemotherapeutic agents in this disease.

Original languageEnglish (US)
Pages (from-to)446-450
Number of pages5
JournalJournal of Clinical Oncology
Volume6
Issue number3
DOIs
Publication statusPublished - Jan 1 1988

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this